Health · Pharma & Biotech · 7 hrs ago
EU approves evolocumab for adults at high cardiovascular risk
The European Union approved evolocumab, sold as Repatha, for adults at high risk of atherosclerotic cardiovascular disease.
This condition involves fatty buildup in the arteries and can lead to heart problems.
The medicine is used alongside treatment to lower blood fats and other steps to address risk factors.
The approval was based on the VESALIUS-CV study.
In that study, evolocumab was linked to a 36% lower risk of a first heart attack.
The expanded approval took effect in the EU in August 2026.
The European Union approved evolocumab for adults at high risk of atherosclerotic cardiovascular disease (ASCVD) in August 2026.
The medicine is to be used alongside treatment to address other risk factors and existing lipid-lowering therapy.
The approval was based on results from the VESALIUS-CV study.
In that study, the risk of a first heart attack was reduced by 36%.
- Who
- Adults at high risk of atherosclerotic cardiovascular disease.
- What
- The EU approved evolocumab to reduce cardiovascular risk.
- When
- August 2026.
- Where
- The European Union.
- Why
- The approval was based on the VESALIUS-CV study, which found a 36% reduction in the risk of a first heart attack.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Medicine
- Repatha® (evolocumab)
- Approval
- European Union, August 2026
- Study
- VESALIUS-CV
- First heart attack risk reduction
- 36%
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Brazil suspends Peptistrong supplement and orders all batches recalled
